Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support the use of shorter regimens will take time to develop. Multi-use pricing is the best option to explore.
‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum
24 February 2021
This blog summarises an initiative taken by more than 300 health economists and experts in support of the creation of an independent health technology assessment agency in Spain.
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
Faster regulatory approval has not necessarily achieved faster patient access. A new OHE paper sets out how risk-sharing can tackle this, enabling resolution of differences of…
OHE at HESG Winter 2021
11 January 2021
Members from the team at OHE attended the Health Economists’ Study Group (HESG) Winter 2021 Meeting, hosted online by the Centre for Health Economics in London,…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
The Value of Vaccines in Maintaining Health System Capacity in England
1 October 2021
This report has now been published as an article in Value in Health available here. The NHS is facing unprecedented health system pressure, with a record number…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…